Trial Profile

A Phase Ib/II, Open-label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic Breast Cancer (Morpheus-panBC)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 24 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Capecitabine (Primary) ; Cobimetinib (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Ladiratuzumab-Vedotin (Primary) ; Selicrelumab (Primary) ; Carboplatin; Eribulin; Gemcitabine; Paclitaxel; Sacituzumab govitecan; Tocilizumab
Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
Focus Adverse reactions; Therapeutic Use
Acronyms Morpheus-panBC
Sponsors Genentech; Roche

28 Nov 2025 Number of treatment arms are increased from 16 to 19 by the addition of 3 more experimental arms comprising new drug combinations with Fulvestrant, Empagliflozin ,Atirmociclib, Palbociclib and metformin.
28 Nov 2025 Planned number of patients changed from 580 to 792.
28 Nov 2025 Planned End Date changed from 3 May 2028 to 30 Sep 2030.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com